Key regions: United Kingdom, Canada, Japan, Europe, China
The Dermatological Drugs market in BRICS has been experiencing significant growth in recent years, with a number of key trends driving this development.
Customer preferences: Consumers in BRICS countries are increasingly seeking out dermatological drugs to address a range of skin conditions, including acne, eczema, and psoriasis. This trend is being driven by a number of factors, including rising levels of disposable income, greater awareness of the importance of skincare, and an aging population.
Trends in the market: One of the key trends in the Dermatological Drugs market in BRICS is the growing demand for prescription medications. This trend is particularly pronounced in Brazil, where a large proportion of the population has access to healthcare and is therefore able to seek out medical treatment for skin conditions. Another trend that is driving growth in the market is the increasing popularity of online pharmacies, which are making it easier for consumers to access a wide range of dermatological drugs.
Local special circumstances: In Brazil, the Dermatological Drugs market is being driven by a number of unique factors, including the country's large and diverse population, its well-developed healthcare system, and the high prevalence of skin conditions among its inhabitants. In Russia, the market is being driven by a growing middle class and an increasing focus on personal grooming and appearance. In India, the market is being driven by a large and growing population, as well as rising levels of disposable income and a growing awareness of the importance of skincare. In China, the market is being driven by an aging population and a growing middle class, both of which are increasingly seeking out dermatological drugs to address a range of skin conditions.
Underlying macroeconomic factors: The growth of the Dermatological Drugs market in BRICS is being driven by a number of underlying macroeconomic factors, including rising levels of disposable income, increasing urbanization, and an aging population. In addition, the market is being fueled by a growing focus on personal grooming and appearance, as well as a greater awareness of the importance of skincare. These factors are expected to continue to drive growth in the Dermatological Drugs market in BRICS in the coming years, making it an attractive market for pharmaceutical companies and investors alike.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
